The Liaoning Provincial Department of Education funding for research projects (grant No. LJKZ0951)

Link to this page

The Liaoning Provincial Department of Education funding for research projects (grant No. LJKZ0951)

Authors

Publications

In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations

Shi, Changzhi; Guo, Kewei; Zhang, Li; Guo, Yi; Feng, Yu; Cvijić, Sandra; Cun, Dongmei; Yang, Mingshi

(MDPI, 2023)

TY  - JOUR
AU  - Shi, Changzhi
AU  - Guo, Kewei
AU  - Zhang, Li
AU  - Guo, Yi
AU  - Feng, Yu
AU  - Cvijić, Sandra
AU  - Cun, Dongmei
AU  - Yang, Mingshi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5080
AB  - Respiratory antibiotics delivery has been appreciated for its high local concentration at the infection sites. Certain formulation strategies are required to improve pulmonary drug exposure and to achieve effective antimicrobial activity, especially for highly permeable antibiotics. This study aimed to investigate lung exposure to various inhalable ciprofloxacin (CIP) formulations with different drug release rates in a rat model. Four formulations were prepared, i.e., CIP-loaded PLGA micro-particles (CHPM), CIP microcrystalline dry powder (CMDP), CIP nanocrystalline dry powder (CNDP), and CIP spray-dried powder (CHDP), which served as a reference. The physicochemical properties, drug dissolution rate, and aerosolization performance of these powders were characterized in vitro. Pharmacokinetic profiles were evaluated in rats. All formulations were suitable for inhalation (mass median aerodynamic diameter < 5 µm). CIP in CHPM and CHDP was amorphous, whereas the drug in CMDP and CNDP remained predominantly crystalline. CHDP exhibited the fastest drug release rate, while CMDP and CNDP exhibited much slower drug release. In addition, CMDP and CNDP exhibited significantly higher in vivo lung exposure to CIP compared with CHDP and CHPM. This study suggests that lung exposure to inhaled drugs with high permeability is governed by drug release rate, implying that lung exposure of inhaled antibiotics could be improved by a sustained-release formulation strategy.
PB  - MDPI
T2  - Pharmaceutics
T1  - In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations
VL  - 15
IS  - 9
DO  - 10.3390/pharmaceutics15092287
ER  - 
@article{
author = "Shi, Changzhi and Guo, Kewei and Zhang, Li and Guo, Yi and Feng, Yu and Cvijić, Sandra and Cun, Dongmei and Yang, Mingshi",
year = "2023",
abstract = "Respiratory antibiotics delivery has been appreciated for its high local concentration at the infection sites. Certain formulation strategies are required to improve pulmonary drug exposure and to achieve effective antimicrobial activity, especially for highly permeable antibiotics. This study aimed to investigate lung exposure to various inhalable ciprofloxacin (CIP) formulations with different drug release rates in a rat model. Four formulations were prepared, i.e., CIP-loaded PLGA micro-particles (CHPM), CIP microcrystalline dry powder (CMDP), CIP nanocrystalline dry powder (CNDP), and CIP spray-dried powder (CHDP), which served as a reference. The physicochemical properties, drug dissolution rate, and aerosolization performance of these powders were characterized in vitro. Pharmacokinetic profiles were evaluated in rats. All formulations were suitable for inhalation (mass median aerodynamic diameter < 5 µm). CIP in CHPM and CHDP was amorphous, whereas the drug in CMDP and CNDP remained predominantly crystalline. CHDP exhibited the fastest drug release rate, while CMDP and CNDP exhibited much slower drug release. In addition, CMDP and CNDP exhibited significantly higher in vivo lung exposure to CIP compared with CHDP and CHPM. This study suggests that lung exposure to inhaled drugs with high permeability is governed by drug release rate, implying that lung exposure of inhaled antibiotics could be improved by a sustained-release formulation strategy.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations",
volume = "15",
number = "9",
doi = "10.3390/pharmaceutics15092287"
}
Shi, C., Guo, K., Zhang, L., Guo, Y., Feng, Y., Cvijić, S., Cun, D.,& Yang, M.. (2023). In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations. in Pharmaceutics
MDPI., 15(9).
https://doi.org/10.3390/pharmaceutics15092287
Shi C, Guo K, Zhang L, Guo Y, Feng Y, Cvijić S, Cun D, Yang M. In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations. in Pharmaceutics. 2023;15(9).
doi:10.3390/pharmaceutics15092287 .
Shi, Changzhi, Guo, Kewei, Zhang, Li, Guo, Yi, Feng, Yu, Cvijić, Sandra, Cun, Dongmei, Yang, Mingshi, "In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations" in Pharmaceutics, 15, no. 9 (2023),
https://doi.org/10.3390/pharmaceutics15092287 . .
1